State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong Special Administrative Region.
Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region.
Eur J Med Chem. 2019 Nov 15;182:111635. doi: 10.1016/j.ejmech.2019.111635. Epub 2019 Aug 22.
The discovery of novel potent neuraminidase (NA) inhibitors remains an attractive approach for treating infectious diseases caused by influenza. In this study, we describe the design and synthesis of novel N-substituted oseltamivir derivatives for probing the 150-cavity which is nascent to the activity site of NA. NA inhibitory studies showed that new derivatives demonstrated the inhibitory activity with IC values at nM level against NA of a clinical influenza virus strain. Moreover, the in silico ADME predictions showed that the selected compounds had comparable properties with oseltamivir carboxylate, which demonstrated the druggablity of these derivatives. Furthermore, molecular docking studies showed that the most potent compound 6f and 10i could adopt different modes of binding interaction with NA, which may provide novel solutions for treating oseltamivir-resistant influenza. Based on the research results, we consider that compounds 6f and 10i have the potential for further studies as novel antiviral agents.
新型强效神经氨酸酶 (NA) 抑制剂的发现仍然是治疗流感引起的传染病的一种有吸引力的方法。在这项研究中,我们描述了新型 N-取代奥司他韦衍生物的设计和合成,用于探测 NA 活性位点之前的 150 腔。NA 抑制研究表明,新衍生物对临床流感病毒株的 NA 具有纳摩尔级别的抑制活性,IC 值。此外,基于计算机的 ADME 预测表明,所选化合物具有与奥司他韦羧酸酯相当的性质,这表明这些衍生物具有成药性。此外,分子对接研究表明,最有效的化合物 6f 和 10i 可以与 NA 采用不同的结合方式,这可能为治疗奥司他韦耐药性流感提供新的解决方案。基于研究结果,我们认为化合物 6f 和 10i 有可能作为新型抗病毒药物进一步研究。